GLAZ-M

GLICLAZIDE BP 80 mg + METFORMIN HYDROCHLORIDE 500 mg.

Gliclazide BP 80 mg + Metformin Hydrochloride 500 mg is an effective oral antidiabetic combination indicated for the management of Type 2 Diabetes Mellitus. This dual-action formulation combines Gliclazide, which stimulates insulin release from the pancreas, with Metformin, which improves insulin sensitivity and reduces glucose production in the liver. Together, they help achieve optimal blood sugar control and reduce the risk of diabetes-related complications.

Benefits & Indications

• Effectively lowers elevated blood glucose levels in Type 2 Diabetes.

• Enhances insulin secretion from pancreatic beta cells.

• Improves insulin sensitivity and glucose utilization by body tissues.

• Reduces hepatic glucose production and intestinal glucose absorption.

• Helps maintain stable fasting and post-meal blood sugar levels.

• Supports long-term glycemic control when combined with diet and exercise.

• Reduces the risk of diabetes-related complications affecting the heart, kidneys, nerves, and eyes.

• Improves overall metabolic health and patient compliance through combination therapy.

Key Features

• Dual-action antidiabetic formulation.

• Provides effective control of fasting and postprandial blood glucose.

• Improves insulin efficiency and glucose metabolism.

• Helps achieve better HbA1c control.

• Suitable for long-term management of Type 2 Diabetes under medical supervision.

Common Indications

• Type 2 Diabetes Mellitus

• Inadequate glycemic control with monotherapy

• Patients requiring combination oral antidiabetic therapy

• Long-term blood glucose management

Mechanism of Action

• Gliclazide stimulates the pancreas to release more insulin.

• Metformin decreases liver glucose production and improves insulin sensitivity, helping the body utilize glucose more effectively.